Sign in

    Kurt Caramanidis • Carl M. Hennig, Inc.

    Kurt Caramanidis is a Senior Research Analyst at Carl M. Hennig, Inc., specializing in U.S. equity research with a focus on small and mid-cap industrials, agriculture, and manufacturing firms. He has provided coverage and analysis on companies like AGCO Corporation, Oshkosh Corporation, and Manitowoc Company, building a reputation for delivering actionable insights and effective investment recommendations. Caramanidis started his financial services career in the early 2000s and joined Carl M. Hennig, Inc. in 2014, following prior roles at regional brokerages in the Midwest. He holds active FINRA Series 7 and 63 licenses and is recognized for his diligent research approach, with performance metrics placing him above peer averages for both recommendation accuracy and average return per call.

    Kurt Caramanidis's questions to S&W Seed Co (SANW) leadership

    Kurt Caramanidis's questions to S&W Seed Co (SANW) leadership • Q2 2025

    Question

    Asked about the VBO joint venture, specifically about any constraints from Shell on selling S&W's position during the strategic review and the potential for the Camelina business to ramp up next year. Also questioned if the company had considered moving to the OTC market to reduce costs.

    Answer

    The company expects the VBO/Camelina business to continue its ramp-up. Regarding the monetization of their VBO stake, they could not provide specifics but stated the board is considering all options to enhance shareholder value. They acknowledged the high cost of being a publicly traded company and confirmed that considering such efficiencies is part of the strategic review process.

    Ask Fintool Equity Research AI

    Kurt Caramanidis's questions to S&W Seed Co (SANW) leadership • Q2 2025

    Question

    Kurt Caramanidis inquired about potential constraints from Shell on monetizing the VBO joint venture during the strategic review, the expected ramp-up of the Camelina business, and whether the company has considered moving to the OTC market to reduce costs.

    Answer

    CEO Mark Herrmann stated he could not comment on specifics regarding the VBO stake beyond noting the board is exploring all options to enhance shareholder value. He expressed confidence in the continued ramp-up of the Camelina business. Regarding a potential move to the OTC market, Herrmann acknowledged the high costs of being a publicly traded company and confirmed that such efficiencies are being considered as part of the overall strategic review.

    Ask Fintool Equity Research AI